RHAMM/CD168 Antibody [Alexa Fluor® 700]

Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

The hyaluronan-mediated motility receptor, also known as RHAMM, was initially identified as a soluble protein that could be released by sub-confluent migrating cells, promoting cell motility and invasion via interactions with hyaluronan (HA) and the cell surface. While RHAMM is normally poorly expressed in most normal tissues and is not required for embryonic development or normal cell homeostasis functions, its expression is increased during wound repair in response to hypoxia and fibrogenic factors. However, its overexpression is transforming in multiple types of cancers and is required for maintaining RAS transformation. RHAMM associates with BRCA1 and BARD1, attenuating the mitotic-spindle-promoting activity of RHAMM, which may contribute to tumor progression by promoting genomic instability.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Images	Ratings	Applications	Species	Date	Details
Enlarge	5 reviewed by: Moyra Lawrence	Flow	Homo sapiens and Human	10/11/2019	View Summary Application Flow Cytometry Sample Tested Megakaryocytes Species Homo sapiens and Human Lot 6189-1502-091619-AF700 Comments Comments 47,000 CD41+CD42+ human iPS-derived megakaryocytes [Moreau et al., 2016] were stained for 20min at room temperature with the indicated quantity of antibody. Cells were then washed in 500uL PBS/BSA/EDTA and viable DAPI- cells were analysed using a Galios flow cytometer.

Array NBP1-76538AF700

• RHAMM/CD168 Antibodies
• RHAMM/CD168 Lysate
• RHAMM/CD168 Proteins